Vpriv is a medication indicated for long-term enzyme replacement therapy for patients with type 1 Gaucher disease. It is designed to replace the missing or deficient glucocerebrosidase enzyme in patients, with a safety and efficacy profile evaluated in a large clinical trial program.
The treatment is available for both treatment-naive patients and those who have previously received disease-specific treatment, offering personalized support programs to help patients initiate and remain on treatment through all life transitions.
Generated from the website